Organizational challenges for partial heart transplantation.

IF 1.6 Q3 CARDIAC & CARDIOVASCULAR SYSTEMS

Future cardiology Pub Date : 2024-01-01 Epub Date: 2024-09-27 DOI:10.1080/14796678.2024.2404775

Vincent S Alexander, Andrew D Vogel, Zachary T Silvano, Herra Javed, Alekhya Mitta, Taufiek Konrad Rajab

引用次数: 0

Abstract

Partial heart transplantation (PHT) has emerged as a new treatment strategy to correct unrepairable heart valve dysfunction in pediatric patients. PHT selectively replaces the dysfunctional components of the recipient's heart and spares the native ventricles. As a result, the transplant biology of PHTs differs from heart transplants. Notably, donor hearts that are unsuitable for whole heart transplantation can be used, graft preservation can be prolonged and immunosuppression levels can be lowered. These nuances of PHT transplant biology have important implications for organizational aspects of PHT clinical application.

查看原文本刊更多论文

部分心脏移植的组织挑战。

部分心脏移植（PHT）已成为一种新的治疗策略，可纠正儿科患者无法修复的心脏瓣膜功能障碍。部分心脏移植选择性地替换受体心脏功能障碍的部分，而保留原生心室。因此，PHT 的移植生物学特性不同于心脏移植。值得注意的是，可以使用不适合全心移植的供体心脏，延长移植体的保存时间，降低免疫抑制水平。PHT 移植生物学的这些细微差别对 PHT 临床应用的组织方面具有重要影响。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Future cardiology CARDIAC & CARDIOVASCULAR SYSTEMS-

CiteScore

2.80

自引率

5.90%

发文量

期刊介绍： Research advances have contributed to improved outcomes across all specialties, but the rate of advancement in cardiology has been exceptional. Concurrently, the population of patients with cardiac conditions continues to grow and greater public awareness has increased patients" expectations of new drugs and devices. Future Cardiology (ISSN 1479-6678) reflects this new era of cardiology and highlights the new molecular approach to advancing cardiovascular therapy. Coverage will also reflect the major technological advances in bioengineering in cardiology in terms of advanced and robust devices, miniaturization, imaging, system modeling and information management issues.